sellWeak cluster of 410b5-1 plan
Mitchell Gold sold $20k of ALPN
Executive Chairman and CEO at ALPINE IMMUNE SCIENCES, INC.. 1,016 shares at an average of $20.04, traded Dec 28, 2023, filed Dec 29, 2023.
Warning score
25Value
$20k
1,016 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$20k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001626199-23-000149, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 28, 2023 | MOption exercise Common Stock10b5-1 | +1,016 | $0.65 | $660 | 1,016 | Dec 29, 2023 |
| Dec 28, 2023 | SOpen-market sale Common Stock10b5-1 | -1,016 | $20.04 | $20k | 0 | Dec 29, 2023 |
| Dec 28, 2023 | MOption exercise Common Stockindirect: Alpine ImmunoSciences, L.P.10b5-1 | +74,441 | $12.74 | $948k | 2,675,421 | Dec 29, 2023 |
| Dec 28, 2023 | FTax withholding Common Stockindirect: Alpine ImmunoSciences, L.P.10b5-1 | -48,264 | $19.65 | $948k | 2,627,157 | Dec 29, 2023 |
| Dec 28, 2023 | MOption exercise Stock Option (Right to buy)derivative10b5-1 | -1,016 | $0.00 | $0 | 247,951 | Dec 29, 2023 |
| Dec 28, 2023 | MOption exercise Warrant (right to buy)derivativeindirect: Alpine ImmunoSciences, L.P.10b5-1 | -74,441 | $0.00 | $0 | 0 | Dec 29, 2023 |
Related signals
Other insiders at ALPINE IMMUNE SCIENCES, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | ALPNsell ALPINE IMMUNE SCIENCES, INC. | James N Topper director | $1,227 19 shares | -0% | |
| 25Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $2.8M 118,000 shares | -50000% | |
| 65Notable | ALPINE IMMUNE SCIENCES, INC. | Orbimed Advisors LLC director | $29M 1,546,347 shares | -42% | |
| 65Notable | ALPINE IMMUNE SCIENCES, INC. | Peter A. Thompson director | $29M 1,546,347 shares | -42% | |
| 50Moderate | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $1.9M 91,884 shares | -243% | |
| 32Weak | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $48k 2,402 shares | -100% | |
| 29Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $292k 15,213 shares | -100% | |
| 40Moderate | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $1.1M 58,787 shares | -507% | |
| 43Moderate | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $2.0M 118,000 shares | -108% | |
| 33Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $1.1M 70,811 shares | -111% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.